NewsRoom Articles - Page 57 of 154 - PsychedelicNewsWire (PNW)

ThursdayJun 02, 2022 3:09 pm

Five Next-Gen Psychedelics Clinical Trials Taking Place in 2022

Numerous studies have shown that psychedelics may be useful in the treatment of mental health conditions, including depression and post-traumatic stress disorder. Companies such as MindMed, Cybin Inc. and Field Trip Health have been conducting clinical trials to test the safety and effectiveness of these medicines in comparison to currently used drugs. Below are some of the next-generation psychedelics that will be in trials this year. Cybin’s CYB003 candidate Cybin’s next-generation psilocybin candidate will enter a phase 1/2a trial this year, after the company receives regulatory approval. The focus of the trial will be the candidate’s effectiveness in treating major…

WednesdayJun 01, 2022 3:16 pm

Oregon Adopts First Installment of Psilocybin Rules

Last week, the Oregon Health Authority adopted new administrative rules to govern testing and training programs for psilocybin as well as psilocybin products. These rules, as well as others that have not yet been finalized, will go into effect in January 2023, when Oregon’s therapeutic psilocybin program begins. Earlier this year, the state published a draft of its proposed directives on psilocybin before it obtained feedback from its residents in April. According to Oregon Psilocybin Services (OPS), since then more than 200 verbal and written comments have been submitted. Consequently, last week OPS released a list of finalized rules, noting…

TuesdayMay 31, 2022 3:30 pm

UC Davis Awarded Grant to Find New Non-hallucinogenic Psychedelic Treatments for Addiction

Scientists at the University of Colorado Anschutz Medical Campus and the University of California Davis are planning to screen compounds in an effort to find new non-hallucinogenic treatments for substance-use disorders. This research will be funded by a $2.7 million grant that was awarded to the institutions by the National Institute on Drug Abuse. The studies are based on evidence from animal and human tests which suggest that psychedelics possess brain-altering effects that could be beneficial in the treatment of addiction. Prior research has also found that psychedelics rewire some regions in the brain that are involved in post-traumatic stress…

TuesdayMay 31, 2022 11:15 am

Silo Pharma Inc. (SILO) Focuses on Psilocybin’s Anti-Inflammatory Properties

On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma focuses on palliative uses of psychedelics for “PTSD, Parkinson’s, and other rare neurological disorders.” In teaming up with TrPR. Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s Disease. Psilocybin’s journey from magic mushrooms to potential life savers has been a long,…

TuesdayMay 31, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain

Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substance Kernel Flow pivotal in developing most accurate, effective treatment regimens for patients The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical…

FridayMay 27, 2022 1:35 pm

VC Executive Shares Insights into Legal Psychedelics Landscape

These past few years, an increasing number of studies on psychedelics have been conducted, with researchers finding that these substances may be used as alternative treatments for mental health conditions such as depression and anxiety. The latest data from World Health Organization shows that the international prevalence of depression and anxiety increased by roughly 25% in the first year of the coronavirus pandemic, and drugs such as psilocybin, MDMA and ketamine are now being studied to develop treatments for everything from depression to PTSD. In a recent interview, some specialized VC’s were asked to give their insights into the psychedelic…

ThursdayMay 26, 2022 1:42 pm

How Psychedelic Treatments Can Become Accessible, Affordable

As the psychedelic industry continues to grow and more is discovered about these compounds and the benefits they hold, concern about whether these treatments will be affordable by the general public increase as well. Last week, Imperial College London research associate Balázs Szigeti stated on Twitter that the lengthy hours needed for psychedelic-assisted therapy would increase the cost of these treatments, making this treatment option more expensive than SSRI treatments, which are cheaper and widely available. This sparked a discussion on what could be done to make psychedelic-assisted therapy equitable and affordable, with safe supply, commercialization, having trained professionals and…

ThursdayMay 26, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds

Recent study indicates psychedelic compounds show significant promise in treating a range of mental-health disorders Participants given psilocybin therapy reported a rapid, sustained improvement in their depression Cybin’s CYB003 has demonstrated less variability, faster onset, shorter duration and better brain penetration than oral psilocybin A new study sponsored by Imperial College London reports that psychedelic compounds may be effective in treating mental-health disorders (https://ibn.fm/xSdZv). The study supports efforts made by Cybin (NEO: CYBN) (NYSE American: CYBN), which is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental-health disorders.…

WednesdayMay 25, 2022 3:11 pm

Davos Hosts Psychedelic Medical Series

With increasing evidence suggesting that psychedelic-assisted therapy may be useful in the treatment of various mental health conditions, including post-traumatic stress disorder, substance-abuse disorders and depression, the emphasis on mental health treatment has grown these last few years. This has been fueled by the fallout of the coronavirus pandemic and the current war in Ukraine. The annual meeting of the World Economic Forum is taking place this week in Davos-Klosters, Switzerland. At the event, top financial and political leaders in the world gather to discuss how to improve the state of the world. Coincidentally, the biggest names in the psychedelics…

TuesdayMay 24, 2022 11:59 am

CSIRO to Collaborate with Biotechnology Firms on Psychedelic Research

The Commonwealth Scientific and Industrial Research Organization (CSIRO), which is the national science agency of Australia, is planning to collaborate with local medical technology firms to develop new psychedelic products while also improving the existing products. The agency’s objective is to develop new psychedelics to help individuals suffering from various mental health conditions, including post-traumatic stress disorder, end-of-life anxiety, addiction and depression. There are many psychedelics in existence, both synthetic and natural alike. CSIRO plans to work with local biomedical firms to extract, synthesize, improve and develop manufacturing processes for up to 15 different psychedelic compounds. Psilocybin is the active…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000